证券代码：603658 证券简称：安图生物 公告编号：2025-040 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"）于2024年12月11日召 开第五届董事会第二次会议、第五届监事会第二次会议，审议通过《关于使用闲 置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金投资项目建 设和募集资金使用的情况下，公司拟分别使用不超过1.7亿元公开发行可转换公 司债券闲置募集资金和不超过17亿元非公开发行股票闲置募集资金进行现金管 理，分别用于购买单次持有期限不超过12个月的结构性存款、大额存单、国债逆 回购、券商收益凭证、券商理财产品等安全性高、流动性好的保本型产品。在上 述额度范围内，资金可在12个月内滚动使用。具体内容详见公司于2024年12月12 日在上海证券交易所网站（www.sse.com.cn）披露的《安图生物关于使用闲置募 集资金进行现金管理的公告》（公告编号：2024-093）。 郑州安图生物工程股份有限公司 关于开立募集资金现金管理产品专用结算账户的 ...

Core Viewpoint - Antu Biology (603658) is actively managing idle fundraising through cash management strategies, indicating a focus on optimizing financial resources while maintaining operational integrity [1][2]. Group 1: Company Performance - As of May 30, 2025, Antu Biology's stock closed at 39.04 CNY, down 0.69% from the previous week [1]. - The company's total market capitalization is 22.308 billion CNY, ranking 7th in the medical device sector and 680th among all A-shares [1]. Group 2: Institutional Research Highlights - During the investor reception event on May 22, 2025, it was revealed that Antu Biology plans to install 72 units of the X-1 production line and 82 units of the A-1/B-1 production lines in 2024 [1][4]. Group 3: Company Announcements - Antu Biology's board approved the use of up to 1.7 billion CNY of idle fundraising for cash management, focusing on safe and liquid principal-protected products with a maximum holding period of 12 months [2]. - The company plans to invest 250 million CNY in structured deposits and large certificates of deposit, with expected yields between 2.05% and 2.90% [1][2]. - As of March 31, 2025, the company's cash reserves were 232.8309 million CNY, with the cash management amount representing 141.73% of the cash reserves [2].

Group 1 - Huapei Power received a project intention letter from a domestic new energy vehicle company for a thermal management system PTC water heater, with an estimated sales amount of approximately 9 million yuan over a 5-year lifecycle starting from 2026 [1] - Antu Biotech obtained medical device registration certificates for products including "Cytomegalovirus IgM Antibody Test Kit" [1][2] - Yihong Technology adjusted the upper limit of its share repurchase price to 65.04 yuan per share, with a total repurchase amount of 6.9583 million yuan for 198,000 shares [2] Group 2 - Aihui Long received a medical device registration certificate for the Hepatitis B virus core antibody detection kit, valid until May 28, 2030 [2][3] - Quanxin Co. plans to engage in commodity futures hedging to mitigate raw material price fluctuations, with a maximum guarantee amount of 8 million yuan [3] - Jiahua Intelligent plans to lease idle assets in Dongguan for a total rental amount of approximately 6.3193 million yuan over 6 years [3] Group 3 - Qianjiang Biochemical announced the resignation of its chairman and a director, with a new chairman to be elected [4][5] - Aerospace Morning Light was suspended from participating in military procurement activities due to violations, with internal investigations underway [6] - Guang'an Aizhong intends to establish a fund with a total scale of 70.7 million yuan, focusing on distributed wind and solar power generation [7] Group 4 - Zhejiang Medicine plans to use up to 1 billion yuan of idle funds for entrusted wealth management, with a maximum investment period of 12 months [10] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS9531 injection, aimed at treating type 2 diabetes patients [11] - Taiji Co. announced the purchase of 10 million yuan in wealth management products, with a minimum holding period of 6 months [12] Group 5 - Hong Kong-listed company Huichuang Pharmaceutical received approval for the clinical trial of a spray for treating primary premature ejaculation [26][27] - Haichuang Pharmaceutical's new drug application for a prostate cancer treatment was approved by the National Medical Products Administration [28] - Zhuhai Guanyu was selected as a designated supplier for low-voltage lithium batteries by SAIC Volkswagen [29] Group 6 - Huayi Technology opened a tax refund service for overseas travelers, enhancing its retail offerings [32] - Baobian Electric plans to transfer 90% of its subsidiary's shares for 137 million yuan [33] - Yiwei Communication intends to invest 100 million yuan to establish a wholly-owned subsidiary to enhance its strategic layout [34]

郑州安图生物工程股份有限公司 关于公司及全资子公司获得医疗器械注册证的公告 证券代码：603658 证券简称：安图生物 公告编号：2025-039 | 编 | 产品名称 | 注册证编号 | 注册证 | 适用范围 / 预期用途 | 所属 | | --- | --- | --- | --- | --- | --- | | 号 | | | 有效期 | | 公司 | | | 巨细胞病毒IgM抗 | 国械注准 | | 本产品用于定性检测人血清或血浆 | | | 1 | 体检测试剂盒（磁 | | 年 5 | 中的巨细胞病毒 IgM 抗体（CMV | | | | 微粒化学发光法） | 20253400892 | | IgM）。 | 安图 | | | 卡马西平检测试剂 | | | | 生物 | | | | 豫械注准 | | 本产品用于体外定量检测人血清样 | | | 2 | 盒（液相色谱-串联 | 20252400400 | 5 年 | 本中卡马西平的含量。 | | | | 质谱法） | | | | | | | | | | 该产品采用基于辣根过氧化物酶和 | | | | | | | 鲁米诺的间接化学发光法，与配套 | | | ...

Core Viewpoint - Antu Biology (603658) has received medical device registration certificates from the National Medical Products Administration and the Henan Provincial Drug Administration for several products, indicating a significant advancement in its product offerings and regulatory compliance [1] Group 1: Product Registration - The company and its wholly-owned subsidiary, Antu Laboratory Instruments (Zhengzhou) Co., Ltd., have obtained registration for the cytomegalovirus IgM antibody test kit (magnetic microparticle chemiluminescence method) [1] - The company has also received registration for the carbamazepine test kit (liquid chromatography-tandem mass spectrometry method) [1] - Additionally, the company has registered several models of fully automated chemiluminescence immunoassay analyzers (AutoLumo S900, AutoLumo S920, AutoLumo S960, AutoLumo S980) [1] Group 2: Application of Products - The fully automated chemiluminescence immunoassay analyzers are designed for qualitative or quantitative detection of analytes from various human-derived samples, including serum, plasma, whole blood, urine, saliva, sputum, cerebrospinal fluid, bronchoalveolar lavage fluid, swab elution fluid, swab processing fluid, and fecal samples [1] - The analyzers can detect tumor-related antigens, liver diseases, hormones, infectious diseases, immune functions, autoantibodies, proteins and peptides, myocardial diseases, vitamins, amino acids, blood drug concentrations, allergens, kidney diseases, coagulation tests, and other enzyme-related and testing projects [1]

证券代码：603658 证券简称：安图生物 公告编号：2025-038 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 现金管理种类：大额存单 现金管理金额：33,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度范 围内，资金可在 12 个月内滚动使用。具体内容详见公司于 2024 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-037 （二）现金管理金额 公司非公开发行股票闲置募集资金 25,000 万元 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 现金管理种类：大额存单 现金管理金额：25,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度 ...

Core Viewpoint - The company has established a dedicated settlement account for cash management of temporarily idle raised funds, ensuring compliance with regulations and enhancing the efficiency of fund utilization [2][3][4]. Group 1: Cash Management Plan - The company plans to use up to 170 million yuan from publicly issued convertible bonds and up to 1.7 billion yuan from non-publicly issued stock for cash management, focusing on safe and liquid financial products [2]. - The cash management will involve purchasing structured deposits, large certificates of deposit, treasury reverse repos, and other high-security, principal-protected products, with a holding period not exceeding 12 months [2][3]. Group 2: Account Establishment - A specialized settlement account for cash management has been opened at Zhengzhou Bank, specifically for the temporarily idle funds from the company's 2020 non-public stock issuance [3]. - The account will only be used for cash management of the raised funds and will not hold non-raised funds or serve other purposes [3]. Group 3: Risk Control Measures - The company will adhere to relevant regulations and guidelines in managing cash, including the Shanghai Stock Exchange rules and company bylaws [4]. - There will be a monitoring system in place to assess potential risks associated with investment products, with independent oversight from the board and audit committee [4]. Group 4: Impact on the Company - The cash management of idle funds will not affect the normal operation of fundraising projects or the company's main business, ensuring that shareholder interests are protected [4]. - This strategy is expected to improve the efficiency of fund utilization and increase returns on cash assets for the company and its shareholders [4].

Investment Rating - The investment rating for the company is "Buy" indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [22]. Core Views - The company's performance is under short-term pressure, with expectations for recovery driven by overseas expansion and domestic market recovery [2][4]. - The company reported a revenue of 4.471 billion (up 0.62% year-on-year) and a net profit of 1.194 billion (down 1.89% year-on-year) for 2024, while Q1 2025 saw a revenue of 996 million (down 8.56% year-on-year) and a net profit of 270 million (down 16.76% year-on-year) [3][5]. - The company is actively responding to centralized procurement impacts, with expectations for recovery in the second quarter of 2026 [5]. Financial Performance - In 2024, the company achieved revenue of 25.56 billion in immunodiagnostics (up 2.91% year-on-year), while biochemical testing revenue was 2.22 billion (down 11.21% year-on-year), and microbiological testing revenue was 3.61 billion (up 11.48% year-on-year) [5]. - The overseas business generated revenue of 284 million in 2024 (up 36.25% year-on-year), indicating strong growth potential [6]. - The company maintained stable expense ratios, with a sales expense ratio of 17.2%, management expense ratio of 4.7%, and R&D expense ratio of 16.4% (up 1.6 percentage points) [6]. Product Development and Market Position - The company launched new products including the AutoChem B2000 and B8000 series of fully automated biochemical analyzers, and the Autof T series of microbial mass spectrometry detection systems [6]. - In the NGS segment, the company’s subsidiary successfully launched three gene sequencers and an automated pathogen analysis system, with further products in trial production [6]. Earnings Forecast and Valuation - The earnings per share (EPS) forecast for 2025-2027 is 2.2, 2.6, and 3.0 respectively, with corresponding price-to-earnings (PE) ratios of 17, 15, and 13 [7]. - The company is recognized as a pioneer in the domestic IVD platform, with increased R&D investment expected to enhance competitiveness [7].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"）于2024年12月11日召 开第五届董事会第二次会议、第五届监事会第二次会议，审议通过《关于使用闲 置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金投资项目建 设和募集资金使用的情况下，公司拟分别使用不超过1.7亿元公开发行可转换公 司债券闲置募集资金和不超过17亿元非公开发行股票闲置募集资金进行现金管 理，分别用于购买单次持有期限不超过12个月的结构性存款、大额存单、国债逆 回购、券商收益凭证、券商理财产品等安全性高、流动性好的保本型产品。在上 述额度范围内，资金可在12个月内滚动使用。具体内容详见公司于2024年12月12 日在上海证券交易所网站（www.sse.com.cn）披露的《安图生物关于使用闲置募 集资金进行现金管理的公告》（公告编号：2024-093）。 证券代码：603658 证券简称：安图生物 公告编号：2025-036 郑州安图生物工程股份有限公司 关于开立募集资金现金管理产品专用结算账户的 公告 ...